Advertisement

AstraZeneca Inks a Deal for Production of at Least 100 Million Doses of Coronavirus Vaccine for the Chinese Market

AstraZeneca Inks a Deal for Production of at Least 100 Million Doses of Coronavirus Vaccine for the Chinese Market

AstraZeneca (NYSE: AZN) has filled a notable gap in its coronavirus vaccine production plans. On Thursday, the sprawling pharmaceutical company announced in a social media post that it had made a deal to have BioKangtai Biologics produce a minimum of 100 million doses of its AZD1222 vaccine candidate in China for that country's immense market. AstraZeneca did not disclose the financial terms of the arrangement, but it did say the collaboration might not remain limited by that country's borders.